GCCA
14.3.2023 14:02:00 CET | Business Wire | Press release
Start-ups from around the world can play a leading role in helping an essential global industry in its efforts to cut CO2 emissions and help solve the climate challenge. They are being invited to apply for the Innovandi Open Challenge, an exciting international partnership programme, run by the Global Cement and Concrete Association (GCCA) and its member companies across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005357/en/
Applications for the 2023 GCCA Innovandi Open Challenge are now open (Graphic: Business Wire)
Applicants are being asked to work on the development of new materials and ingredients for low carbon concrete – a major step towards the ultimate goal of net zero concrete.
Innovation can help further unlock the delivery of low carbon concrete by reducing the amount of clinker used - the carbon intensive element of cement - or by using the most cutting-edge manufacturing processes. Alternative materials, including construction and demolition waste, can result in much lower CO2 emissions than concrete made in the traditional method, as well as reduce the need to use virgin raw materials.
The global challenge matches start-up companies with some of the world’s leading cement and concrete manufacturers, who operate in almost every country across the world, to work on initiatives to cut emissions and pioneer environmental change across the industry.
The GCCA and its members account for 80% of global cement production capacity outside of China, as well as some key Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete (which currently account for around 7% globally), through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.
The launch follows the success of last year’s first ever Innovandi Open Challenge, which saw cement companies partnering with six start-ups, with a strong focus on carbon capture and utilisation projects. Three of those projects have already gone to pilot stage.
Thomas Guillot, Chief Executive of the GCCA, said:
“We’re calling on the best and the brightest from around the world to join us in the urgent fight to limit global warming and help towards delivering the great prize of net zero concrete. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology, then we want to hear from you.”
“Concrete is the second most used substance on earth after water and is a vital part of our modern infrastructure. The GCCA and all our members are working hard to reduce emissions. And start-ups can play a big role in helping us to do that.”
Start-ups can find more information and apply to take part in the Innovandi Open Challenge by going to the GCCA Open Challenge webpage:
https://gccassociation.org/innovandi/openchallenge/oc2023
Those companies who are accepted for this year’s Innovandi Open Challenge, will gain unique access to industry plants, labs, key networks and the expertise and infrastructure of the GCCA’s 40 members from around the world. They will also receive guidance from the GCCA and its members to help them with the development of new technology and business cases.
Claude Loréa, GCCA Cement Director and Innovation Lead said:
“We’ve already seen some remarkable progress from those start-ups who’ve been working with our members on the first Innovandi Open Challenge, with several projects already in the pilot stage. This year’s theme, low carbon concrete, is equally challenging. To succeed, we need products which are affordable, scalable, and easily adopted. Good luck to all this year’s applicants. We look forward to working with those selected.”
Natalie Giglio is Senior Business Development Associate, at Carbon Upcycling Technologies in Canada, which took part in the first Innovandi Open Challenge. She encourages all start-ups interested in working on net-zero initiatives to apply:
"The Innovandi program is specifically designed to foster collaboration among the largest global cement producers, and start-ups, which is an opportunity unique to this challenge. Our initiative focused on validating materials at the lab scale, and now the results have set a foundation for further collaboration and project development.”
/ Ends
Notes to editors:
The Innovandi Open Challenge is open to applicants from 14th March 2023, with applications closing on 30th May 2023.
For more information click here:
Additional quotes from start-ups which have taken part in the 1st Innovandi Open Challenge:
Carbon BioCapture is based in the USA and has patented technology for CO2 capture using microalgae (microscopic algae invisible to the naked eye.) CEO Andrea Irarrazaval said: “It has been a great opportunity and an honour for Carbon BioCapture (CBC) to be selected in GCCA's Open Challenge global programme… Participation provides valuable means for tech start-ups to access, obtain growth assistance, and help to demonstrate their technology potential to the critical cement and concrete global industry."
CarbonOrO, based in the Netherlands, specializes in carbon capture technology using unique bi-phasic amine. Spokesperson Jan Hoppenbrouwers said: “There is a lot of talk about carbon capture, utilisation and storage but worldwide, we need to accelerate the number of pilots and move towards commercial scale roll-out. GCCA members and their consortia’s joined efforts have all the characteristics to change this. So, our advice, participate in this challenge.”
Coomtech based in the UK, has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture. Founder Chris Every said: “Coomtech took part in the Innovandi Open Challenge to showcase its technology at a global level to the cement and concrete industry. Innovandi has been highly supportive and is commercially attuned to new technologies. The connections the program makes are an excellent springboard for emerging technology businesses focused on the vital cement and concrete sector.”
Fortera, based in the USA, uses technology to capture CO2 emissions from cement plants, combining it with calcium oxide to make reactive calcium carbonate. Vice President Kas Farsad, said: “The Innovandi Open Challenge platform allowed Fortera to engage multiple cement players simultaneously and really dig into not just industry pain points, but brainstorm on solutions with the broader industry in mind. Whether you're looking to launch a pilot plant or to validate a commercial offering, you'll get a committed consortium of GCCA members supporting your process."
MOF Technologies, based in the UK, is using modern sorbents called metal-organic frameworks (MOFs) to engineer a filtration system to capture and remove CO2 from flue gas. Conor Hamill, Co-CEO said: “Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to have had the opportunity to collaborate with GCCA members to bring our technology to the field. We are currently working with an innovative consortium to pilot our ultra-efficient Nuada technology which will validate its potential to provide the industry with a scalable low-cost carbon capture solution.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
